等待开盘 07-26 09:30:00 美东时间
-0.040
-0.22%
Ligand Pharmaceuticals announced it will release its Q2 2025 financial results on August 7, 2025, followed by a conference call at 8:30 AM ET to discuss the results and provide a business update. The call will be accessible via phone (800) 715-9871 (US/Canada) or (646) 307-1963 (international) using conference ID 3661098, or via live/replay webcast available online. Ligand, a biopharmaceutical company, focuses on advancing high-value medicines th...
07-24 11:00
Fusion Fuel Green PLC subsidiary BrightHy Solutions has entered into a non-binding term sheet with a strategic partner for up to €30 million in investments over four years in mid-scale hydrogen infrastructure projects. The partnership aims to deliver sustainable and financially viable hydrogen solutions, with each project evaluated against specific benchmarks. BrightHy Solutions will manage the investment entity under a 10-year agreement, subject...
07-22 12:00
Fulgent Genetics (NASDAQ:FLGT) has received European Union’s CE certification for its germline next-generation sequencing system. This system includes FulgentExome and Fulgent Pipeline Manager, compl...
07-17 22:16
新浪财经ESG评级中心提供包括资讯、报告、培训、咨询等在内的14项ESG服务,助力上市公司传播ESG理念,提升ESG可持续发展表现。点击查看【 ESG评级中...
06-24 07:00
Nutex Health (NASDAQ:NUTX) is set to give its latest quarterly earnings report ...
05-13 03:03
Fulgent Genetics (NASDAQ:FLGT) stock jumped on Friday after it reported both first quarter revenue and profit above expectations, as its business saw strong growth in all segments. The company posted ...
05-02 23:45
Fulgent Genetics (NASDAQ:FLGT) affirms FY2025 GAAP EPS guidance from $(1.95) to $(1.95) vs $(1.34) analyst estimate..
05-02 19:04
Fulgent Genetics (NASDAQ:FLGT) is preparing to release its quarterly earnings o...
05-02 02:03
Hotel & Resort REIT Ryman Hospitality Properties (NYSE:RHP) is set to join the S&P SmallCap 600 index, effective prior to trading open on March 24. The move is a part of the latest changes to the S&P ...
03-10 19:54
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1104327819967434752.png</p><span style="color:#999999;">编者按:每日追踪华尔街最新评级与目标价,挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• 摩根大通:维持Syndax制药(SNDX)"超配"评级,目标价从35美元升至39美元</p> <p>• 摩根大通:维持AnaptysBio(ANAB)"超配"评级,目标价从36美元升至42美元</p> <p>• 摩根大通
03-06 11:20